Compare CASH & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | XERS |
|---|---|---|
| Founded | 1954 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1996 | 2021 |
| Metric | CASH | XERS |
|---|---|---|
| Price | $73.72 | $9.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $101.00 | $12.29 |
| AVG Volume (30 Days) | 181.5K | ★ 1.9M |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 6.29 | N/A |
| Revenue | ★ $839,894,000.00 | $49,590,000.00 |
| Revenue This Year | N/A | $32.77 |
| Revenue Next Year | $5.69 | $24.06 |
| P/E Ratio | $11.37 | ★ N/A |
| Revenue Growth | 11.29 | ★ 142.67 |
| 52 Week Low | $65.93 | $5.25 |
| 52 Week High | $101.26 | $10.09 |
| Indicator | CASH | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 19.64 | 67.03 |
| Support Level | $70.38 | $7.15 |
| Resistance Level | $84.06 | N/A |
| Average True Range (ATR) | 1.49 | 0.46 |
| MACD | -0.38 | 0.18 |
| Stochastic Oscillator | 2.81 | 85.23 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.